Visit the RepliCel Life Sciences Investor Hub
Ubika Research has recently published a new information report on RepliCel Life Sciences Inc. (TSXV: RP), a regenerative medicine company focused on developing autologous cell therapies for multi-billion dollar markets that address diseases caused by a deficit of healthy cells required for normal healing and function, such as chronic tendinosis, damaged skin and pattern baldness. READ THE REPORT >>
To get breaking news and interviews with the company, follow RepliCel Life Sciences Inc. News
RepliCel Life Sciences Inc. is a featured sponsored company and has paid SmallCapPower.com a fee for coverage.
